5 Ritanserin and ICI 170,809 had no effect on apomorphine-induced stereotypy or hyperactivity, indicating that these drugs do not produce non-specific behavioural activation. 6 Ritanserin and ICI 170,809 inhibited quipazine-induced wet dog shakes at doses similar to those enhancing the 5-HT behavioural syndrome.
Introduction 5-Hydroxytryptamine (5-HT) receptors in the central nervous system are currently classified into three broad categories, 5-HT1, 5-HT2 and 5-HT3 (Peroutka & Snyder, 1979; Bradley et al., 1986; Kilpatrick et al., 1987) . Further, have been subdivided into 5-HTlA, 5-HTID subtypes (Pedigo et al., 1981; Pazos et al., 1984; Herrick-Davis & Titeler, 1988) .
A number of drugs showing selectivity for the 5-HT1 receptor sub-types exist. In particular, several compounds with both high affinity and selectivity for the 5-HTlA receptor have been identified. These include 8-OH-DPAT (8-hydroxy-2-(din-propylamino)tetralin) and gepirone, both of which have an affinity (Ki in the nm range) for the 5-HTlA binding site in rat brain membranes which exceeds by several orders of magnitude their affinity for either the 5-HT1B, 5-HT1c, 5-HTID or 5-HT2 recognition sites (Middlemiss & Fozard, 1983; Peroutka, 1985; Hoyer, 1988a) . The classical 5-HT agonist 5- MeODMT (5-methoxy-N,N-dimethyltryptamine) displays high affinity for the 5-HTlA binding site with somewhat less affinity for the 5-HT1B, 5-HT1c and 5-HT1D binding sites (Sills et al., 1984; Hoyer, 1988a) .
Administration of 8-OH-DPAT (Hjorth et al., 1982) , gepirone (Eison et al., 1986) or (Grahame-Smith, 1971) to rats results in a complex behavioural syndrome similar to the behaviour seen following administration of 5-HT precursors or 5-HT releasers (see, for example, Grahame-Smith, 1971; Green & Grahame-Smith, 1974; Jacobs, 1976) . The fact that the behavioural syndrome induced by 8-OH-DPAT and 5-MeODMT is, firstly, antagonized by pindolol and propranolol stereoselectively and by other compounds with high affinity for the 5-HT1A site (Lucki et al., 1984; Tricklebank et al., 1984; 1985; Sharp et al., 1990) and, secondly, unchanged by lesion of 5-HT neurones or inhibition of 5-HT synthesis (Trulson et al., 1976; Deakin & Green, Author for correspondence.
1978; Hjorth et al., 1982; Tricklebank et al., 1984) , argues strongly for the involvement of postsynaptic in the 5-HT behavioural syndrome.
Previously, Goodwin & Green (1985) found that pretreatment with ritanserin enhanced hyperactivity in rats induced by the 5-HT1 agonist RU 24969 and, on the basis of the then known antagonist properties of ritanserin (Leysen et al., 1985; Colpaert et al., 1985) , suggested that there might be a functional interaction between central 5-HT2 and 5-HT1 receptors. However, it is now recognised that ritanserin only has a slightly greater selectivity for 5-HT2 than 5-HT1c binding sites (Hoyer, 1988ab) . This is also the case for the recently developed, potent 5-HT2 antagonist, IC 170,809 (Blackburn et al., 1988; Blackburn personal communication) . On the other hand, ketanserin has been shown to have 70 fold greater affinity for 5-HT2 versus 5-HT1c binding sites (Hoyer, 1988a) . This study investigated the effects of ritanserin, ICI 170,809 and ketanserin on the 5-HT behavioural syndrome induced in rats by drugs active at 5-HTlA receptors.
Methods

Animals
Albino male Sprague-Dawley rats, 200-250 g, (Harlan Olac, Bicester, U.K.) were housed at the department for at least one week before being used in the experiments. Animals were kept in groups of 6-7 under conditions of controlled temperature (21 + 1°C) and lighting (dark period 19 h 00 min-7 h 00min) with free access to food and water. All experiments were performed during the light phase of the cycle between 10h 00min and 16h 00min.
Behavioural observations
For measurement of the 5-HT behavioural syndrome, rats were placed in individual clear Plexiglass cages with a layer of (D Macmiflan Press Ltd, 1990 sawdust covering the bottom, five to ten minutes before drug administration. Individual components of the syndrome (head weaving, forepaw treading, hind limb abduction, flat body posture) were scored during observation periods of 45 s per rat on a 4-point ranked intensity scale (0 = absent, 1 = equivocal, 2 = definite, 3 = extreme: Deakin & Green, 1978 To measure wet dog shake behaviour, rats were placed singly in clear Plexiglass cages 5-10 min before drug administration. The number of wet dog shakes was counted over 40 min after administration of quipazine, according to the procedure of Vetulani et al. (1980) . Wet dog shakes were characterized as rapid side to side twitches of the head and ears, as previously described (Bedard & Pycock, 1977 by 2mgkg-' 5-MeODMT (Figure 7 ). In this experiment, hindlimb abduction and flat body posture tended to increase but the change did not reach statistical significance (P < 0.075). However, the total behavioural score was significantly increased.
Pretreatment with ICI 170,809 (5mg kg-I s.c.) before saline administration did not produce any components of the 5-HT behavioural syndrome when scored for 60 min (data not shown).
Effect of ketanserin on the 8-OH-DPAT-and S-MeODMT-induced S-HT behavioural syndrome
As shown in Figure 8a pretreatment with low and high doses of ketanserin (0.25 and 2.5mgkg-' s.c.) had different effects on the 5-HT behavioural syndrome induced by 8-OH-DPAT (0.75mgkg-' s.c.). At the lower dose, ketanserin significantly (P < 0.05) increased 8-OH-DPAT-induced hindlimb abduction, flat body posture and total syndrome score and also tended to* augment headweaving and forepaw treading (P < 0.1). At the higher dose, ketanserin tended to reduce all four behavioural components.
Pretreatment with low and high doses of ketanserin (0.25 and 2.5 mg kg-'1 s.c.) also had a differential effect on the 5-HT behavioural syndrome when induced by 5-MeODMT (2 mg kg s.c.) (Figure 8b ). At the lower dose, ketanserin significantly increased the hindlimb abduction, flat body posture Effect of ritanserin and ICI 170,809 on quipazine-induced wet dog shake behaviour Both ritanserin and ICI 170,809 were tested for their ability to antagonize quipazine-induced wet dog shakes in rats, a model which has been used as an in vivo test of central 5-HT2 receptor function. Ritanserin (0.05-1 mg kg-l s.c.) significantly and dose-dependently (ID50 = 0.092mgkg-1) inhibited wet dog shake behaviour induced by quipazine administration (5mg kg-1 i.p.) (Figure 9a ). Pretreatment with 1 mg kgritanserin completely abolished the production of wet dog shake behaviour by quipazine.
ICI 170,809 (0.05-5mg kg-1 s.c.) also significantly and.
dose-dependently (ID50 = 1.41 mgkg-') inhibited quipazineinduced wet dog shake behaviour (5 mg kg-1 i.p.) (Figure 9b ). Pretreatment with 5mgkg-1 ICI 170,809 completely abolished the production of wet dog shake behaviour by quipazine.
Discussion
The activity induced by a submaximally effective dose of the dopamine agonist apomorphine. These latter findings suggest that ritanserin and ICI 170,809 do not enhance the 5-HT behavioural syndrome through non-specific activation. It is unlikely that these drugs act by inhibiting the metabolism of the 5-HTlA agonists, since those used have a markedly different chemical structure and most probably do not have a common metabolic pathway. Both ritanserin and ICI 170,809 potently inhibited wet dog shake behaviour induced by quipazine in rats, a model which has previously been used as an in vivo test of 5-HT2 receptor function (Vetulani et al., 1980; Colpaert & Janssen, 1983; Yap & Taylor, 1983) . In fact, the relationship between dose and effect for inhibiting wet dog shake behaviour and for enhancing the behavioural syndrome coincided well for each compound. For example, ritanserin almost completely abolished quipazine-induced wet dog shake behaviour at a dose (0.4mg kg-1) which produced maximal enhancement of 8-OH-DPAT-induced behaviour. However, in the light of the similarities between the pharmacology of the 5-HT2 and 5-HT1c receptors (see Hoyer, 1988b) , it cannot be certain that quipazine-induced wet dog shakes occur solely through activation of 5-HT2 receptors.
In a low dose ketanserin, which also has 5-HT2 antagonist activity (Leysen et al., 1981) , also potentiated the 5-HT behavioural syndrome, while a higher dose of the drug inhibited the response. Previously, higher doses of ketanserin have been shown to inhibit the 8-OH-DPAT and 5-MeODMT-induced behavioural syndrome (Tricklebank et al., 1984; 1985) . The blockade of the 5-HT behavioural syndrome by higher doses of ketanserin might arise from actions on other receptors or other neurotransmitters, in particular the a1-adrenoceptor for which ketanserin is a potent ligand (Leysen et al., 1981) . In the present study, we found that the al-adrenoceptor antagonist prazosin markedly reduced the 5-HT behavioural syndrome induced by 8-OH-DPAT, confirming the findings of Tricklebank et al. (1984) . Ketanserin also has actions on dopamine receptors and both this study and that of Tricklebank et al. observed blockade of the 8-OH-DPAT-induced syndrome by the dopamine antagonist haloperidol. Thus, enhancement of the 5-HT behavioural syndrome by a low dose of ketanserin could reflect the preferential 5-HT2 antagonist action of the drug, whereas al-adrenoceptor and/or dopamine antagonism might account for the high dose inhibition of the 8-OH-DPAT-and 5-MeODMT-induced behavioural syndrome. Antagonism of catecholamine receptors might also explain the results of earlier studies, which demonstrated that putative 5-HT2 antagonists including spiperone and pirenperone decreased various components of the 5-HT behavioural syndrome (Ortmann et al., 1982; Green et al., 1983; Goodwin & Green, 1985) . In one study, Goodwin & Green (1985) found that ritanserin had no effect on the 8-OH-DPAT-induced behavioural syndrome, although a maximally effective dose of 8-OH-DPAT (3 mg kg-' s.c.) was used (cf. Figure 5 ).
Both ritanserin and ICI 170,809 were recently shown to have an affinity for the central 5-HT1c binding site which was only slightly less than that for the 5-HT2 binding site (Hoyer, 1988a; Blackburn personal communication) . However, it has been found that ritanserin at doses larger than those used here is not active in a putative behavioural model of 5-HT1c function (Kennett & Curzon, 1988) . In addition, ketanserin, shows at least a 70 fold greater affinity for 5-HT2 versus 5-HT1c receptors (Hoyer, 1988a (Lakoski & Aghajanian, 1985) . Concurrent microiontophoretic application of another putative 5-HT2 antagonist, TR2515, similarly enhances the depressant effect of 5-HT, lysergic acid diethylamide (LSD) and 8-OH-DPAT on dorsal raphe neurones (Blier et al., 1989) . (3 (Weiss et al., 1986) . (4) In man, ritanserin enhances the 5-HT, receptor-mediated increase of plasma prolactin and growth hormone induced by L-tryptophan (Charig et al., 1986) .
Recently, Arnt & Hyttel (1989) found that pretreatment with the putative 5-HT2 agonist 1-(2,5-dimethoxy-4iodoph-enyl-2-aminopropane (DOI) (Shannon et al., 1984) enhanced 8-OH-DPAT-induced forepaw treading in rats. Further, it was suggested that stimulation of 5-HT2 receptors has a permissive role on the expression of the 5-HTlA function, which would appear to conflict with the conclusions of the present study. However, there is evidence that at least some aspects of the 5-HT behavioural syndrome can be induced by 5-HT2 as well as 5-HTIA receptor activation. For example, we have observed that high doses of DOI induce a behavioural syndrome which is not unlike that of 8-OH-DPAT and which is sensitive to ritanserin (Wang et al., unpublished observation). Furthermore, Goodwin & Green (1985) found that the behavioural syndrome induced by the 5-HT agonist quipazine is attenuated by both ritanserin and the 5-HT1//i-adrenoceptor antagonist propranolol. In a model to account for the present findings and those of others, the 5-HT behavioural syndrome might be produced by stimulation of a population of either 5-HTlA or 5-HT2 receptors, with the former being under the inhibitory influence of a sub-population of 5-HT2 receptors.
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